AEterna Zentaris Inc. (AEZS)

[DorseyE]

Aeterna Expects Top-Line Phase 3 Data in April Evaluating Zoptrex in Endometrial Cancer [EC]

Aeterna (NASDAQ:AEZS) is the smallest company on this list, having just two approved products and a market cap of only $40MM. APIFINY® is the only non-PSA based blood test for prostate cancer, and Saizen is approved for growth hormone replacement therapy in children and adults.

The company has yet to break even, but has several key catalysts in 2017 for their two main candidates Zoptrex and Macrilen. AEZS has already completed out-licensing deals in numerous non-US territories, and Zoptrex could become the first FDA-approved therapy for advanced recurrent Endometrial Cancer [EC].

The company plans to submit an NDA in EC this year if Phase 3 data is positive, and the drug is also in Phase 2 development for ovarian cancer and prostate cancer. Sitting far below their 52-week high of $5.59, there is plenty of opportunity for movement here and investors should be watching AEZS closely. The outcome of the Phase 3 ZoptEC trial will be an important one to watch.

https://seekingalpha.com/article/4061076-watch-q2-upcoming-healthcare-data-releases